Becton Dickinson Total Liabilities 2010-2025 | BDX
Becton Dickinson total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Becton Dickinson total liabilities for the quarter ending March 31, 2025 were $29.226B, a 2.51% increase year-over-year.
- Becton Dickinson total liabilities for 2024 were $31.396B, a 16.35% increase from 2023.
- Becton Dickinson total liabilities for 2023 were $26.984B, a 2.42% decline from 2022.
- Becton Dickinson total liabilities for 2022 were $27.652B, a 8.4% decline from 2021.
Becton Dickinson Annual Total Liabilities
(Millions of US $) |
| 2024 |
$31,396 |
| 2023 |
$26,984 |
| 2022 |
$27,652 |
| 2021 |
$30,189 |
| 2020 |
$30,247 |
| 2019 |
$30,684 |
| 2018 |
$32,910 |
| 2017 |
$24,786 |
| 2016 |
$17,953 |
| 2015 |
$19,314 |
| 2014 |
$7,394 |
| 2013 |
$7,106 |
| 2012 |
$7,225 |
| 2011 |
$5,602 |
| 2010 |
$4,216 |
| 2009 |
$4,162 |
Becton Dickinson Quarterly Total Liabilities
(Millions of US $) |
| 2025-03-31 |
$29,226 |
| 2024-12-31 |
$29,460 |
| 2024-09-30 |
$31,396 |
| 2024-06-30 |
$29,714 |
| 2024-03-31 |
$28,510 |
| 2023-12-31 |
$26,942 |
| 2023-09-30 |
$26,984 |
| 2023-06-30 |
$27,080 |
| 2023-03-31 |
$28,705 |
| 2022-12-31 |
$27,657 |
| 2022-09-30 |
$27,652 |
| 2022-06-30 |
$27,706 |
| 2022-03-31 |
$30,261 |
| 2021-12-31 |
$29,203 |
| 2021-09-30 |
$30,189 |
| 2021-06-30 |
$30,199 |
| 2021-03-31 |
$30,094 |
| 2020-12-31 |
$30,085 |
| 2020-09-30 |
$30,247 |
| 2020-06-30 |
$29,937 |
| 2020-03-31 |
$32,565 |
| 2019-12-31 |
$30,750 |
| 2019-09-30 |
$30,684 |
| 2019-06-30 |
$30,736 |
| 2019-03-31 |
$31,289 |
| 2018-12-31 |
$31,528 |
| 2018-09-30 |
$32,910 |
| 2018-06-30 |
$32,620 |
| 2018-03-31 |
$33,421 |
| 2017-12-31 |
$34,116 |
| 2017-09-30 |
$24,786 |
| 2017-06-30 |
$24,579 |
| 2017-03-31 |
$16,158 |
| 2016-12-31 |
$16,735 |
| 2016-09-30 |
$17,953 |
| 2016-06-30 |
$17,983 |
| 2016-03-31 |
$18,570 |
| 2015-12-31 |
$18,823 |
| 2015-09-30 |
$19,314 |
| 2015-06-30 |
$19,826 |
| 2015-03-31 |
$21,134 |
| 2014-12-31 |
$13,435 |
| 2014-09-30 |
$7,394 |
| 2014-06-30 |
$6,996 |
| 2014-03-31 |
$6,935 |
| 2013-12-31 |
$6,957 |
| 2013-09-30 |
$7,106 |
| 2013-06-30 |
$6,871 |
| 2013-03-31 |
$7,041 |
| 2012-12-31 |
$7,160 |
| 2012-09-30 |
$7,225 |
| 2012-06-30 |
$6,790 |
| 2012-03-31 |
$6,719 |
| 2011-12-31 |
$6,686 |
| 2011-09-30 |
$5,602 |
| 2011-06-30 |
$5,322 |
| 2011-03-31 |
$5,245 |
| 2010-12-31 |
$5,193 |
| 2010-09-30 |
$4,216 |
| 2010-06-30 |
$3,878 |
| 2010-03-31 |
$3,794 |
| 2009-12-31 |
$3,834 |
| 2009-09-30 |
$4,162 |
| 2009-06-30 |
$3,637 |
| 2009-03-31 |
$2,772 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$49.119B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
